Midnight Dec 6 was the deadline for patient submission of comments to be considered in the FDA’s Dec 20 public review of Ampligen for potential approval as an Rx treatment for ME/CFS.
Now, patients & advocates are invited to view the live webcast of this public review on Dec 20, 8 am to 5 pm Eastern time. Oral testimony is scheduled for approximately 1 pm to 2:30 pm Eastern time.
The FDA has indicated it will post details, including the web address for the webcast and background material for the meeting, sometime on Dec 18 at this FDA site: http://www.fda.gov/AdvisoryCommittees/Calendar/ucm324972.htm.
The FDA also plans to post the webcast in its archive for later viewing.